Demand exceeding supply in high-margin products

– Inderes
Lataa raportti (PDF)Tämä raportti on vain Inderes Premium -käyttäjille.
We reiterate our 7.7 EUR target and accumulate-recommendation for Okmetic after the Q2-report. Okmetic’s Q2 results were strong as was anticipated and the report did not change our view of the company of the investment case. A slight upside in the share price is supported by moderate earnings multiples, high dividend yield and attractive long term growth outlook in the industry.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille